NewAmsterdam Pharma Company N.V.
HealthcareNASDAQ:NAMS · NASDAQ Capital Market
+$0.14 today
Vol 0.67M · Avg 1.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.8%
avg -34.6%
ROIC
-33.0%
avg -30.8%
ROA
-26.5%
avg -29.4%
Analysis
ROA is currently the strongest return metric at -26.5% versus its period average of -29.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | $1.14M | — | 70 | $617,851.00 | 0.53% |
Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | $808,143.00 | — | 72 | $69,302.00 | 0.06% |
Douglas F. Kling | Chief Operating Officer | $790,051.00 | — | 53 | $95,043.00 | 0.08% |
Mayur Amrat Somaiya | Chief Financial Officer | $770,393.00 | — | 52 | $82,744.00 | 0.07% |
Louise Kooij | Chief Accounting Officer | $695,419.00 | — | 50 | $84,353.00 | 0.07% |
Juliette Audet | Chief Strategy & Business Officer | $653,039.00 | — | 39 | $30,000.00 | 0.03% |
Marc Ditmarsch | Chief Development Officer | — | — | 59 | — | — |
Chris Deluzio | Executive Vice President of Sales Enterprise Operations | — | — | — | — | — |
Bob Rambo | Executive Vice President of Marketing | — | — | — | — | — |
Michael F. Marino | Chief Legal Officer & Corporate Secretary | — | — | 50 | $617,851.00 | 0.53% |
Maryellen McQuade | Chief People Officer | — | — | — | — | — |
Matthew Philippe | Executive VP & Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$295,267.47
Sells
47
$65.23M
Net Sentiment
$64.93M
Net selling
Most Active
Kooij Louise Frederika
15 transactions
1–10 of 53
Analysis
Insiders reported 6 buys worth $295,267.47 and 47 sells worth $65.23M over the last 12 months. That adds up to net selling of $64.93M. Kooij Louise Frederika was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | +71.1% (6yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +71.1% (6yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Arcellx, Inc.
ACLX
$6.73B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Who manages NAMS?
NewAmsterdam Pharma Company N.V. (NAMS) lists 12 active executives. The top listed executive is Juliette Audet, Chief Strategy & Business Officer.
Are NAMS insiders buying or selling?
Recent insider activity shows net selling of $45.29M.
Explore More
Continue the stock analysis
Jump to another research area for this company.